Biogen

News

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

News

In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.

News

Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.

News

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

News

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.